http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 20 Feb 2026 07:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/BioStem+Technologies+to+Present+at+the+46th+Annual+TD+Cowen+Healthcare+Conference/26032823.html <p align="justify">POMPANO BEACH, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jBFKYRuyzri9UWvfY7yQ_t4nMHAin2MJWoDtp2jE6EeQtyNpSE4U1CSDfFveviyfVD88NKScorI-ewyWG8ciUJL8OkPfdmz4Yz-rimNGNmzbxPGeTtcvjJALm8uCjw3389UtjLX0lYiT1L26xk4yk4hWK9_EGHNwKbNPjOZBpCrkjoNNjGbCvYG_du9yCLrf_DbLasaeSuTDlSHBE66o9BMbp195Z18B-QQwVV-h6fhpwf61K6aVZxQ-C8r82rdMbnCZ2KMt1ySuwKWj5vxaHrOnCye_4LLtu0po-GBqTUsko9gV6PlKSXoxs3J_E4NIdMQ40ZSiihDfpHOBbBBWHjmdyQuddmK1XpwrJs5xk-MFZ9RfsBOBHBNk5XH2FfcfUBjgQtJINVhxvouoLtqjLA==" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today announced that Company management will present at the 46th Annual TD Cowen Healthcare Conference being held in Boston, MA.</p> <p align="justify"><strong>46</strong><strong>th</strong><strong> Annual TD Cowen Healthcare Conference: </strong></p> <ul type="disc"><li style="text-align:justify;">Format: Presentation</li><li style="text-align:justify;">Date: Monday, March 2, 2026</li><li style="text-align:justify;">Time: 3:50 pm ET<br/></li></ul> <p align="justify">Interested parties may access live and archived webcasts of the presentations on the “investors” section http://www.streetinsider.com/Press+Releases/BioStem+Technologies+to+Present+at+the+46th+Annual+TD+Cowen+Healthcare+Conference/26032823.html Fri, 20 Feb 2026 07:00:00 -0500 A.50113823 BSEM O.00725546 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+to+Present+at+the+46th+Annual+TD+Cowen+Healthcare+Conference/26032823.html <p align="justify">POMPANO BEACH, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jBFKYRuyzri9UWvfY7yQ_t4nMHAin2MJWoDtp2jE6EeQtyNpSE4U1CSDfFveviyfVD88NKScorI-ewyWG8ciUJL8OkPfdmz4Yz-rimNGNmzbxPGeTtcvjJALm8uCjw3389UtjLX0lYiT1L26xk4yk4hWK9_EGHNwKbNPjOZBpCrkjoNNjGbCvYG_du9yCLrf_DbLasaeSuTDlSHBE66o9BMbp195Z18B-QQwVV-h6fhpwf61K6aVZxQ-C8r82rdMbnCZ2KMt1ySuwKWj5vxaHrOnCye_4LLtu0po-GBqTUsko9gV6PlKSXoxs3J_E4NIdMQ40ZSiihDfpHOBbBBWHjmdyQuddmK1XpwrJs5xk-MFZ9RfsBOBHBNk5XH2FfcfUBjgQtJINVhxvouoLtqjLA==" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today announced that Company management will present at the 46th Annual TD Cowen Healthcare Conference being held in Boston, MA.</p> <p align="justify"><strong>46</strong><strong>th</strong><strong> Annual TD Cowen Healthcare Conference: </strong></p> <ul type="disc"><li style="text-align:justify;">Format: Presentation</li><li style="text-align:justify;">Date: Monday, March 2, 2026</li><li style="text-align:justify;">Time: 3:50 pm ET<br/></li></ul> <p align="justify">Interested parties may access live and archived webcasts of the presentations on the “investors” section http://www.streetinsider.com/Press+Releases/BioStem+Technologies+to+Present+at+the+46th+Annual+TD+Cowen+Healthcare+Conference/26032823.html Fri, 20 Feb 2026 07:00:00 -0500 A.50113823 BSEM O.00725546 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+to+Present+at+the+46th+Annual+TD+Cowen+Healthcare+Conference/26032823.html <p align="justify">POMPANO BEACH, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jBFKYRuyzri9UWvfY7yQ_t4nMHAin2MJWoDtp2jE6EeQtyNpSE4U1CSDfFveviyfVD88NKScorI-ewyWG8ciUJL8OkPfdmz4Yz-rimNGNmzbxPGeTtcvjJALm8uCjw3389UtjLX0lYiT1L26xk4yk4hWK9_EGHNwKbNPjOZBpCrkjoNNjGbCvYG_du9yCLrf_DbLasaeSuTDlSHBE66o9BMbp195Z18B-QQwVV-h6fhpwf61K6aVZxQ-C8r82rdMbnCZ2KMt1ySuwKWj5vxaHrOnCye_4LLtu0po-GBqTUsko9gV6PlKSXoxs3J_E4NIdMQ40ZSiihDfpHOBbBBWHjmdyQuddmK1XpwrJs5xk-MFZ9RfsBOBHBNk5XH2FfcfUBjgQtJINVhxvouoLtqjLA==" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today announced that Company management will present at the 46th Annual TD Cowen Healthcare Conference being held in Boston, MA.</p> <p align="justify"><strong>46</strong><strong>th</strong><strong> Annual TD Cowen Healthcare Conference: </strong></p> <ul type="disc"><li style="text-align:justify;">Format: Presentation</li><li style="text-align:justify;">Date: Monday, March 2, 2026</li><li style="text-align:justify;">Time: 3:50 pm ET<br/></li></ul> <p align="justify">Interested parties may access live and archived webcasts of the presentations on the “investors” section http://www.streetinsider.com/Press+Releases/BioStem+Technologies+to+Present+at+the+46th+Annual+TD+Cowen+Healthcare+Conference/26032823.html Fri, 20 Feb 2026 07:00:00 -0500 A.50113823 BSEM O.00725546 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+to+Present+at+the+46th+Annual+TD+Cowen+Healthcare+Conference/26032823.html <p align="justify">POMPANO BEACH, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jBFKYRuyzri9UWvfY7yQ_t4nMHAin2MJWoDtp2jE6EeQtyNpSE4U1CSDfFveviyfVD88NKScorI-ewyWG8ciUJL8OkPfdmz4Yz-rimNGNmzbxPGeTtcvjJALm8uCjw3389UtjLX0lYiT1L26xk4yk4hWK9_EGHNwKbNPjOZBpCrkjoNNjGbCvYG_du9yCLrf_DbLasaeSuTDlSHBE66o9BMbp195Z18B-QQwVV-h6fhpwf61K6aVZxQ-C8r82rdMbnCZ2KMt1ySuwKWj5vxaHrOnCye_4LLtu0po-GBqTUsko9gV6PlKSXoxs3J_E4NIdMQ40ZSiihDfpHOBbBBWHjmdyQuddmK1XpwrJs5xk-MFZ9RfsBOBHBNk5XH2FfcfUBjgQtJINVhxvouoLtqjLA==" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today announced that Company management will present at the 46th Annual TD Cowen Healthcare Conference being held in Boston, MA.</p> <p align="justify"><strong>46</strong><strong>th</strong><strong> Annual TD Cowen Healthcare Conference: </strong></p> <ul type="disc"><li style="text-align:justify;">Format: Presentation</li><li style="text-align:justify;">Date: Monday, March 2, 2026</li><li style="text-align:justify;">Time: 3:50 pm ET<br/></li></ul> <p align="justify">Interested parties may access live and archived webcasts of the presentations on the “investors” section http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+to+Present+at+the+46th+Annual+TD+Cowen+Healthcare+Conference/26032823.html Fri, 20 Feb 2026 07:00:00 -0500 A.50113823 BSEM O.00725546 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+to+Present+at+the+46th+Annual+TD+Cowen+Healthcare+Conference/26032823.html <p align="justify">POMPANO BEACH, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jBFKYRuyzri9UWvfY7yQ_t4nMHAin2MJWoDtp2jE6EeQtyNpSE4U1CSDfFveviyfVD88NKScorI-ewyWG8ciUJL8OkPfdmz4Yz-rimNGNmzbxPGeTtcvjJALm8uCjw3389UtjLX0lYiT1L26xk4yk4hWK9_EGHNwKbNPjOZBpCrkjoNNjGbCvYG_du9yCLrf_DbLasaeSuTDlSHBE66o9BMbp195Z18B-QQwVV-h6fhpwf61K6aVZxQ-C8r82rdMbnCZ2KMt1ySuwKWj5vxaHrOnCye_4LLtu0po-GBqTUsko9gV6PlKSXoxs3J_E4NIdMQ40ZSiihDfpHOBbBBWHjmdyQuddmK1XpwrJs5xk-MFZ9RfsBOBHBNk5XH2FfcfUBjgQtJINVhxvouoLtqjLA==" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today announced that Company management will present at the 46th Annual TD Cowen Healthcare Conference being held in Boston, MA.</p> <p align="justify"><strong>46</strong><strong>th</strong><strong> Annual TD Cowen Healthcare Conference: </strong></p> <ul type="disc"><li style="text-align:justify;">Format: Presentation</li><li style="text-align:justify;">Date: Monday, March 2, 2026</li><li style="text-align:justify;">Time: 3:50 pm ET<br/></li></ul> <p align="justify">Interested parties may access live and archived webcasts of the presentations on the “investors” section http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+to+Present+at+the+46th+Annual+TD+Cowen+Healthcare+Conference/26032823.html Fri, 20 Feb 2026 07:00:00 -0500 A.50113823 BSEM O.00725546 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+to+Present+at+the+46th+Annual+TD+Cowen+Healthcare+Conference/26032823.html <p align="justify">POMPANO BEACH, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jBFKYRuyzri9UWvfY7yQ_t4nMHAin2MJWoDtp2jE6EeQtyNpSE4U1CSDfFveviyfVD88NKScorI-ewyWG8ciUJL8OkPfdmz4Yz-rimNGNmzbxPGeTtcvjJALm8uCjw3389UtjLX0lYiT1L26xk4yk4hWK9_EGHNwKbNPjOZBpCrkjoNNjGbCvYG_du9yCLrf_DbLasaeSuTDlSHBE66o9BMbp195Z18B-QQwVV-h6fhpwf61K6aVZxQ-C8r82rdMbnCZ2KMt1ySuwKWj5vxaHrOnCye_4LLtu0po-GBqTUsko9gV6PlKSXoxs3J_E4NIdMQ40ZSiihDfpHOBbBBWHjmdyQuddmK1XpwrJs5xk-MFZ9RfsBOBHBNk5XH2FfcfUBjgQtJINVhxvouoLtqjLA==" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today announced that Company management will present at the 46th Annual TD Cowen Healthcare Conference being held in Boston, MA.</p> <p align="justify"><strong>46</strong><strong>th</strong><strong> Annual TD Cowen Healthcare Conference: </strong></p> <ul type="disc"><li style="text-align:justify;">Format: Presentation</li><li style="text-align:justify;">Date: Monday, March 2, 2026</li><li style="text-align:justify;">Time: 3:50 pm ET<br/></li></ul> <p align="justify">Interested parties may access live and archived webcasts of the presentations on the “investors” section http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+to+Present+at+the+46th+Annual+TD+Cowen+Healthcare+Conference/26032823.html Fri, 20 Feb 2026 07:00:00 -0500 A.50113823 BSEM O.00725546 http://www.streetinsider.com/Corporate+News/BioStem+Technologies+notes+FDA+support+for+bayesian+trial+methods/25938665.html <p>BioStem Technologies Inc. (OTC: BSEM) said recent comments from FDA Commissioner Martin Makary supporting expanded use of Bayesian statistical methodologies in clinical trials align with the company's research approach.</p><p>The company said it used Bayesian regression and hurdle modeling in a published study of its BioRetain-processed allografts for diabetic foot ulcers. The statistical methods enabled quantification of wound closure probability and treatment effects across different patient populations, according to the company.</p><p>BioStem's study showed that BioRetain-processed allografts were almost twice as likely to achieve lasting wound closure compared to standard care alone when using complete closure rather than initial closure as the http://www.streetinsider.com/Corporate+News/BioStem+Technologies+notes+FDA+support+for+bayesian+trial+methods/25938665.html Tue, 03 Feb 2026 16:07:32 -0500 BSEM http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html <p>POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=i3yxAeV14N8grigg0cJ4YAMPbAWFDkVAdgrZBNkzdC1JXb315GeRf0Cd1Hm0dXYE1uI3Gh8sgqknSY52de01p-JdxHOoimbgk0zYFoeOWdFJSqHddAmUwPCsFkboU0GS" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis.</p> <p>FDA Commissioner, Dr. Martin Makary recently described the agency’s evolving stance on Bayesian approaches as a “leap forward” for clinical science, noting their potential to improve trial design, dose optimization, pediatric http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html Tue, 03 Feb 2026 16:05:00 -0500 A.06822034 A.50113823 BSEM O.00725546 O.20026344 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html <p>POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=i3yxAeV14N8grigg0cJ4YAMPbAWFDkVAdgrZBNkzdC1JXb315GeRf0Cd1Hm0dXYE1uI3Gh8sgqknSY52de01p-JdxHOoimbgk0zYFoeOWdFJSqHddAmUwPCsFkboU0GS" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis.</p> <p>FDA Commissioner, Dr. Martin Makary recently described the agency’s evolving stance on Bayesian approaches as a “leap forward” for clinical science, noting their potential to improve trial design, dose optimization, pediatric http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html Tue, 03 Feb 2026 16:05:00 -0500 A.06822034 A.50113823 BSEM O.00725546 O.20026344 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html <p>POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=i3yxAeV14N8grigg0cJ4YAMPbAWFDkVAdgrZBNkzdC1JXb315GeRf0Cd1Hm0dXYE1uI3Gh8sgqknSY52de01p-JdxHOoimbgk0zYFoeOWdFJSqHddAmUwPCsFkboU0GS" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis.</p> <p>FDA Commissioner, Dr. Martin Makary recently described the agency’s evolving stance on Bayesian approaches as a “leap forward” for clinical science, noting their potential to improve trial design, dose optimization, pediatric http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html Tue, 03 Feb 2026 16:05:00 -0500 A.06822034 A.50113823 BSEM O.00725546 O.20026344 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html <p>POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=i3yxAeV14N8grigg0cJ4YAMPbAWFDkVAdgrZBNkzdC1JXb315GeRf0Cd1Hm0dXYE1uI3Gh8sgqknSY52de01p-JdxHOoimbgk0zYFoeOWdFJSqHddAmUwPCsFkboU0GS" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis.</p> <p>FDA Commissioner, Dr. Martin Makary recently described the agency’s evolving stance on Bayesian approaches as a “leap forward” for clinical science, noting their potential to improve trial design, dose optimization, pediatric http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html Tue, 03 Feb 2026 16:05:00 -0500 A.06822034 A.50113823 BSEM O.00725546 O.20026344 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html <p>POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=i3yxAeV14N8grigg0cJ4YAMPbAWFDkVAdgrZBNkzdC1JXb315GeRf0Cd1Hm0dXYE1uI3Gh8sgqknSY52de01p-JdxHOoimbgk0zYFoeOWdFJSqHddAmUwPCsFkboU0GS" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis.</p> <p>FDA Commissioner, Dr. Martin Makary recently described the agency’s evolving stance on Bayesian approaches as a “leap forward” for clinical science, noting their potential to improve trial design, dose optimization, pediatric http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html Tue, 03 Feb 2026 16:05:00 -0500 A.06822034 A.50113823 BSEM O.00725546 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html <p>POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=i3yxAeV14N8grigg0cJ4YAMPbAWFDkVAdgrZBNkzdC1JXb315GeRf0Cd1Hm0dXYE1uI3Gh8sgqknSY52de01p-JdxHOoimbgk0zYFoeOWdFJSqHddAmUwPCsFkboU0GS" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis.</p> <p>FDA Commissioner, Dr. Martin Makary recently described the agency’s evolving stance on Bayesian approaches as a “leap forward” for clinical science, noting their potential to improve trial design, dose optimization, pediatric http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html Tue, 03 Feb 2026 16:05:00 -0500 A.06822034 A.50113823 BSEM O.00725546 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html <p>POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=i3yxAeV14N8grigg0cJ4YAMPbAWFDkVAdgrZBNkzdC1JXb315GeRf0Cd1Hm0dXYE1uI3Gh8sgqknSY52de01p-JdxHOoimbgk0zYFoeOWdFJSqHddAmUwPCsFkboU0GS" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis.</p> <p>FDA Commissioner, Dr. Martin Makary recently described the agency’s evolving stance on Bayesian approaches as a “leap forward” for clinical science, noting their potential to improve trial design, dose optimization, pediatric http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html Tue, 03 Feb 2026 16:05:00 -0500 A.06822034 A.50113823 BSEM O.00725546 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html <p>POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=i3yxAeV14N8grigg0cJ4YAMPbAWFDkVAdgrZBNkzdC1JXb315GeRf0Cd1Hm0dXYE1uI3Gh8sgqknSY52de01p-JdxHOoimbgk0zYFoeOWdFJSqHddAmUwPCsFkboU0GS" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis.</p> <p>FDA Commissioner, Dr. Martin Makary recently described the agency’s evolving stance on Bayesian approaches as a “leap forward” for clinical science, noting their potential to improve trial design, dose optimization, pediatric http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html Tue, 03 Feb 2026 16:05:00 -0500 A.06822034 A.50113823 BSEM O.00725546 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html <p>POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=i3yxAeV14N8grigg0cJ4YAMPbAWFDkVAdgrZBNkzdC1JXb315GeRf0Cd1Hm0dXYE1uI3Gh8sgqknSY52de01p-JdxHOoimbgk0zYFoeOWdFJSqHddAmUwPCsFkboU0GS" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis.</p> <p>FDA Commissioner, Dr. Martin Makary recently described the agency’s evolving stance on Bayesian approaches as a “leap forward” for clinical science, noting their potential to improve trial design, dose optimization, pediatric http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html Tue, 03 Feb 2026 16:05:00 -0500 A.06822034 A.50113823 BSEM O.00725546 O.20026344 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html <p>POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=i3yxAeV14N8grigg0cJ4YAMPbAWFDkVAdgrZBNkzdC1JXb315GeRf0Cd1Hm0dXYE1uI3Gh8sgqknSY52de01p-JdxHOoimbgk0zYFoeOWdFJSqHddAmUwPCsFkboU0GS" rel="nofollow" target="_blank">BioStem Technologies, Inc.</a> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived products for advanced wound care, today underscored the significance of recent remarks from U.S. Food and Drug Administration (FDA) leadership signaling openness to expanded use of Bayesian statistical methodologies in clinical trial design and analysis.</p> <p>FDA Commissioner, Dr. Martin Makary recently described the agency’s evolving stance on Bayesian approaches as a “leap forward” for clinical science, noting their potential to improve trial design, dose optimization, pediatric http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Highlights+Alignment+with+FDA%E2%80%99s+Openness+to+Bayesian+Statistical+Approaches+in+Clinical+Research/25938556.html Tue, 03 Feb 2026 16:05:00 -0500 A.06822034 A.50113823 BSEM O.00725546 O.20026344 http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html <div class="xn-content"> <p class="prntac"><i>BioTissue Deepens Commitment to Ocular Market Leadership</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.miami" idsrc="xmltag.org" >MIAMI</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <span>BioTissue Holdings, Inc</span>, a leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, today announced the completion of the sale of its non-ocular Surgical and <span value="ACORN:4284452801" idsrc="xmltag.org" >Wound Care</span> business to <span value="ACORN:5011382362" idsrc="xmltag.org" >BioStem Technologies, Inc.</span> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html Wed, 21 Jan 2026 18:00:00 -0500 A.21823961 A.42844528 A.50113823 BESM BSEM O.00725546 O.13287785 O.36703937 http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html <div class="xn-content"> <p class="prntac"><i>BioTissue Deepens Commitment to Ocular Market Leadership</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.miami" idsrc="xmltag.org" >MIAMI</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <span>BioTissue Holdings, Inc</span>, a leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, today announced the completion of the sale of its non-ocular Surgical and <span value="ACORN:4284452801" idsrc="xmltag.org" >Wound Care</span> business to <span value="ACORN:5011382362" idsrc="xmltag.org" >BioStem Technologies, Inc.</span> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html Wed, 21 Jan 2026 18:00:00 -0500 A.21823961 A.42844528 A.50113823 BESM BSEM O.00725546 O.13287785 O.36703937 http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html <div class="xn-content"> <p class="prntac"><i>BioTissue Deepens Commitment to Ocular Market Leadership</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.miami" idsrc="xmltag.org" >MIAMI</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <span>BioTissue Holdings, Inc</span>, a leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, today announced the completion of the sale of its non-ocular Surgical and <span value="ACORN:4284452801" idsrc="xmltag.org" >Wound Care</span> business to <span value="ACORN:5011382362" idsrc="xmltag.org" >BioStem Technologies, Inc.</span> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html Wed, 21 Jan 2026 18:00:00 -0500 A.21823961 A.42844528 A.50113823 BESM BSEM O.00725546 O.13287785 O.36703937 http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html <div class="xn-content"> <p class="prntac"><i>BioTissue Deepens Commitment to Ocular Market Leadership</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.miami" idsrc="xmltag.org" >MIAMI</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <span>BioTissue Holdings, Inc</span>, a leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, today announced the completion of the sale of its non-ocular Surgical and <span value="ACORN:4284452801" idsrc="xmltag.org" >Wound Care</span> business to <span value="ACORN:5011382362" idsrc="xmltag.org" >BioStem Technologies, Inc.</span> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html Wed, 21 Jan 2026 18:00:00 -0500 A.21823961 A.42844528 A.50113823 BESM BSEM O.00725546 O.13287785 O.36703937 http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html <div class="xn-content"> <p class="prntac"><i>BioTissue Deepens Commitment to Ocular Market Leadership</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.miami" idsrc="xmltag.org" >MIAMI</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <span>BioTissue Holdings, Inc</span>, a leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, today announced the completion of the sale of its non-ocular Surgical and <span value="ACORN:4284452801" idsrc="xmltag.org" >Wound Care</span> business to <span value="ACORN:5011382362" idsrc="xmltag.org" >BioStem Technologies, Inc.</span> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html Wed, 21 Jan 2026 18:00:00 -0500 A.21823961 A.42844528 A.50113823 BESM BSEM O.00725546 O.13287785 O.36703937 http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html <div class="xn-content"> <p class="prntac"><i>BioTissue Deepens Commitment to Ocular Market Leadership</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.miami" idsrc="xmltag.org" >MIAMI</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <span>BioTissue Holdings, Inc</span>, a leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, today announced the completion of the sale of its non-ocular Surgical and <span value="ACORN:4284452801" idsrc="xmltag.org" >Wound Care</span> business to <span value="ACORN:5011382362" idsrc="xmltag.org" >BioStem Technologies, Inc.</span> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html Wed, 21 Jan 2026 18:00:00 -0500 A.21823961 A.42844528 A.50113823 BESM BSEM O.00725546 O.13287785 O.36703937 http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html <div class="xn-content"> <p class="prntac"><i>BioTissue Deepens Commitment to Ocular Market Leadership</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.miami" idsrc="xmltag.org" >MIAMI</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <span>BioTissue Holdings, Inc</span>, a leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, today announced the completion of the sale of its non-ocular Surgical and <span value="ACORN:4284452801" idsrc="xmltag.org" >Wound Care</span> business to <span value="ACORN:5011382362" idsrc="xmltag.org" >BioStem Technologies, Inc.</span> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html Wed, 21 Jan 2026 18:00:00 -0500 A.21823961 A.42844528 A.50113823 BESM BSEM O.00725546 O.13287785 O.36703937 http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html <div class="xn-content"> <p class="prntac"><i>BioTissue Deepens Commitment to Ocular Market Leadership</i></p><p><span class="legendSpanClass"><location value="LU/us.fl.miami" idsrc="xmltag.org" >MIAMI</location></span>, <span class="legendSpanClass"><chron>Jan. 21, 2026</chron></span> /PRNewswire/ -- <span>BioTissue Holdings, Inc</span>, a leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, today announced the completion of the sale of its non-ocular Surgical and <span value="ACORN:4284452801" idsrc="xmltag.org" >Wound Care</span> business to <span value="ACORN:5011382362" idsrc="xmltag.org" >BioStem Technologies, Inc.</span> (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/BioTissue+Holdings%2C+Inc+Strengthens+Strategic+Focus+on+Ocular+Innovation+with+Sale+of+Surgical+and+Wound+Care+Business+to+BioStem+Technologies/25876594.html Wed, 21 Jan 2026 18:00:00 -0500 A.21823961 A.42844528 A.50113823 BESM BSEM O.00725546 O.13287785 O.36703937